Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added @ 8.88 & 8.90
Anyone see this or know where to go feedback?
Leukemia Treatment Virtually Eradicates Cancer, Kills 'Pounds' Of Cancerous Cells
http://www.huffingtonpost.com/2011/08/10/leukemia-shot-kills-cancer_n_923700.html?icid=maing-grid10%7Chtmlws-main-bb%7Cdl8%7Csec3_lnk3%7C85439
Has this board DOA???????????
You need to go back to mid 2010 to get less of the trading-type posts. Less wining would be nice
I added to my position @ 12.42 & 12.13
oK thanks, see you at ARIA
its ok with me if you don't care to answer but have you sold all your shares?
Anything to gain by holding or are we flat at this price level? Will selling or holding make any difference in a lawsuit if there are any awards?
Thoughts please. Thanks
So do you (we) have something here to ride out, or do you fold and at what price?
Any one here???? Icagen Next on Pfizer's RadarPrint Share
By: Zacks Equity Research
July 22, 2011 | Comments: 0
Recommended this article (2)
PFE | ICGN After the significant acquisitions of Wyeth and King Pharmaceuticals, Pfizer Inc. (PFE - Analyst Report) has set its aim at Icagen Inc. (ICGN - Snapshot Report) as the pharma-major inked an agreement to acquire the latter. Pfizer already owns around 11% of Icagen’s shares and will pay $6.00 per share for the remaining 89% or 8.3 million shares.
At this point, is the consensus to hold, If so, why?
What can we expect?
If we SELL and a court reverses the merger do we recover loss of value?
If hold, what chance do we have
Are the PR pusher culpable?
Explain Laughable, please.
Thanks
Tripp Levy PLLC Announces Investigation of IcagenLast update: 7/20/2011 9:13:00 AMNEW YORK, Jul 20, 2011 (BUSINESS WIRE) -- Tripp Levy PLLC, a leading national securities law firm, announces an investigation into the proposed acquisition of Icagen, Inc. (ICGN) by Pfizer Inc. (PFE). Pfizer, which currently owns approximately 11% of Icagen's shares, will acquire the remaining shares it does not already own at a price of $6.00 per share. The aggregate transaction value, including the value of the shares currently owned by Pfizer, is approximately $56 million.The investigation concerns, among other things, whether the consideration to be paid to Icagen shareholders is unfair, inadequate, and substantially below the fair or inherent value of Icagen. Indeed, the buyout price of $6 represents a "discount" to where the stock traded just prior to the announced ($7.75), and analysts estimate the stock is worth at least $8 per share. The investigation further concerns whether the board of directors of Icagen may have breached their fiduciary duties by not acting in Icagen shareholders' best interests in connection with the sale process of Icagen. If you own Icagen common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact: Tripp LevyTripp Levy PLLC125 East 82nd Street9th FloorNew York, New YorkToll Free: 877-772-3975Email: contact@tripplevy.com
Where do you get this info? Thanks
“Getting pounded even before the early hours to the public. had a 10k block at 8.3”
When will Micromet cancer drug development deal with Amgen translate into PPS increase?
And is anyony hear?
Should we expect Pfizer to announce merger news today and if so would it be typically after market close?
surferbj-- Can you rephrase –
“Not to big for PFE./ICGN merger and much higher stock price on future drug sales if ICGN does not merge and holds same share count”??
I’m not getting what you said.
Thank you
What is going on with this stock?????
I’ve been wrong more then right
I think it’s fools gold and is going to drop back to 6.20s
Micromet Announces Solid Tumor BiTE Antibody Collaboration With Amgen
Biocompare
http://www.biocompare.com/News/NewsStory/384941/Micromet-Announces-Solid-Tumor-BiTE-Antibody-Collaboration-With-Amgen.html
Source: BUSINESS WIRE
Wednesday, July 13, 2011
• Collaboration on up to three targets and two programs
• Upfront payment of €10 million upon deal execution
• Maximum deal value of €695 million plus royalties and development cost reimbursement
ROCKVILLE, Md.--July 11, 2011--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI) announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, to be selected by Amgen.
“The BiTE antibody provides an innovative approach to cancer therapy,” said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. “Amgen is pleased to collaborate with the Micromet scientific team to deploy this technology against targets for the treatment of solid tumors.”
Under the terms of the agreement, Amgen is expected to pay €10 million upon deal execution. If milestones in multiple indications and tumor types are achieved, Micromet is eligible to receive up to €342 million in clinical and commercial milestone payments. Micromet is also eligible to receive up to double-digit royalties on worldwide net sales.
For the second BiTE program, Micromet is eligible to receive an additional cash payment upon initiation of the program, milestones, royalties and development funding comparable to the first program. The combined potential payments to Micromet from both programs, excluding reimbursement of research and development costs, are approximately €695 million. The initial development plan contemplates €25 million in funding of Micromet R&D activities if two BiTE antibodies are advanced to IND. All expected costs associated with the research, development and commercialization of the BiTE antibodies will be borne by Amgen.
Micromet will be primarily responsible for the discovery and pre-clinical development of the BiTE antibodies. Amgen will lead the clinical development, manufacturing, and commercialization of any products resulting from the collaboration.
“We are very pleased to collaborate with Amgen, an industry leader with a proven track record of success in oncology and biologics,” said Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer. "This collaboration aligns well with our strategy to expand development of BiTE antibodies into solid tumor indications with support from a partner and brings important non-dilutive capital into the company."
About BiTE Antibodies
BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.
July 12, 2011 Amarin initiated with a Buy at MKM Partners (pre-open) Target $23
http://www.theflyonthewall.com/permalinks/entry.php/AMRNid1456325/AMRN-Amarin-initiated-with-a-Buy-at-MKM-Partners-preopen
theflyonthewall.com
invest2win, want to thank you for all your posts. You only look lonely out there, your not. You just have something worth saying and I usually don’t. Thanks
Amarin management to meet with Morgan Joseph
News Breaks
July 11, 2011
11:26 EDT AMRN theflyonthewall.com: Amarin management to meet with Morgan Joseph
Meeting to be held in New York on July 14-15 hosted by Morgan Joseph. :theflyonthewall.com
http://www.theflyonthewall.com/permalinks/entry.php/AMRNid1455618/AMRN-Amarin-management-to-meet-with-Morgan-Joseph
Pfizer mulls acquisition of Icagen
Today
Eleanor Malone
eleanor.malone@informa.com
Pfizer is considering a "strategic transaction" with partner Icagen, which could include the acquisition of the latter, according to a filing it has made with the US Securities and Exchange Commission (SEC). As of 30 April, Pfizer owns around 14.2% of Icagen's stock.
Icagen has agreed to...
http://www.scripintelligence.com/business/Pfizer-mulls-acquisition-of-Icagen-317904
There was some talk about a week ago that we should expect a dilution coming at us. Any thoughts on this and how bad a drop in POS we’d see?
where did $10 go??
Target $25 Amarin initiated with a Buy at Morgan Joseph
http://www.theflyonthewall.com/permalinks/entry.php/AMRNid1444084/AMRN-Amarin-initiated-with-a-Buy-at-Morgan-Joseph
June 14, 2011
09:13 EDT AMRN theflyonthewall.com: Amarin initiated with a Buy at Morgan Joseph
Target $25. :theflyonthewall.com
Life signs >>>>???? Any educated guesses on direction?
ARIAD to Present at the Jefferies 2011 Global Healthcare Conference
Last update: 6/1/2011 7:35:00 AM
CAMBRIDGE, Mass., Jun 01, 2011 (BUSINESS WIRE) -- ARIAD Pharmaceuticals, Inc. (ARIA) today announced that it will present at the Jefferies 2011 Global Healthcare Conference being held at the Grand Hyatt Hotel in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's strong oncology pipeline on Wednesday, June 8 at 9:30 a.m. (ET).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at . A replay of the presentation will also be available and archived on the site for 90 days.
About ARIAD
ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit .
http://custom.fmg.dowjones.com/custom/tdameritrade-com/html-story.asp?guid=%7B4f3715ef-dc6f-4eae-9db1-184ccd070e6e%7D
No- just got home, saw it and posted it with hopes someone on the board with more insight then me would be enlightening
News Breaks
Ariad management to meet with Leerink
Field trip to company headquarters in Cambridge, MA will be held on May 18 at 12 pm hosted by Leerink.
http://www.theflyonthewall.com/permalinks/entry.php/ARIAid1430956/ARIA-Ariad-management-to-meet-with-Leerink
Actually it was a senior moment, thanks for humoring me. I had the info.
when is the ASCO?
when is the ASCO
I’m a rookie, please define pig in connection to “ARIA acting like a pig”. Thank you
Does anyone out there want to share there outline of how they see events unfolding short term (wk's) and from now to the end of the year? If and when will we see stock dilution?
What would Merck or another company's buyout look like for us?
Who owns the stinking outhouse where all this brilliant dumping is coming from?